Best response to rituximab according to the primary site of lymphoma localization and previous chemotherapy in 34 evaluable patients
Response . | No prior chemotherapy, n = 23 . | Prior chemotherapy, n = 11 . | Primary gastric site, n = 14* . | Primary nongastric site, n = 20 . | All patients, n = 34 . |
|---|---|---|---|---|---|
| ORR (%) | 20 (87)† | 5 (45)† | 9 (64) | 16 (80) | 25 (73) |
| CR (%) | 11 (48) | 4 (36) | 4 (29) | 11 (55) | 15 (44) |
| PR (%) | 9 (39) | 1 (9) | 5 (35) | 5 (25) | 10 (29) |
| SD (%) | 2 (9) | 4 (36) | 4 (29) | 2 (10) | 6 (18) |
| PD (%) | 1 (4) | 2 (18) | 1 (7) | 2 (10) | 3 (9) |
Response . | No prior chemotherapy, n = 23 . | Prior chemotherapy, n = 11 . | Primary gastric site, n = 14* . | Primary nongastric site, n = 20 . | All patients, n = 34 . |
|---|---|---|---|---|---|
| ORR (%) | 20 (87)† | 5 (45)† | 9 (64) | 16 (80) | 25 (73) |
| CR (%) | 11 (48) | 4 (36) | 4 (29) | 11 (55) | 15 (44) |
| PR (%) | 9 (39) | 1 (9) | 5 (35) | 5 (25) | 10 (29) |
| SD (%) | 2 (9) | 4 (36) | 4 (29) | 2 (10) | 6 (18) |
| PD (%) | 1 (4) | 2 (18) | 1 (7) | 2 (10) | 3 (9) |